A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of the Combination of Duvortuxizumab With Ibrutinib in Subjects With B-Cell Malignancies
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Duvortuxizumab (Primary) ; Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Janssen
- 22 Nov 2017 Planned End Date changed from 1 Mar 2020 to 31 Mar 2020.
- 22 Nov 2017 Planned primary completion date changed from 1 Sep 2018 to 30 Sep 2018.
- 22 Nov 2017 Planned initiation date changed from 31 Jul 2016 to 20 Jul 2016.